BIS Research Study Highlights the Global Cell and Gene Therapy Drug Delivery Devices Market to Reach $10.82 Billion by 2030 investigated in the latest…

Posted: March 24, 2021 at 12:46 pm

The global cell and gene therapy drug delivery devices market was valued at $55.75 thousand in 2019, and is expected to reach $375.13 thousand by 2030, registering a CAGR of 16.61% during the forecast.

The global cell and gene therapy drug delivery devices marketis projected to reach $375.13 thousand by 2030, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 16.61% during the period between 2020 and 2030.

The comprehensive study of global cell and gene therapy drug delivery devices market BIS Research extensively covers the following:

The detailed study is a compilation of 19 Market Data Tables and 184 Figures spread through 315 Pages and in-depth TOC bisresearch.com/industrarket.html

Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, and segmental analysis.

BIS Research study indicates that the increasing global geriatric population, prevalence of genetic disorders, the increased demand for gene therapeutics that not only cure the chronic conditions completely but also improve the quality of life of the patients are the major factors anticipated to contribute to the growth of the global cell and gene therapy drug delivery devices market.

The study highlights the various emerging opportunities, such as strong pipeline and drug approvals of cell and gene therapies, introduction of cell and gene therapy drug delivery devices, potential technologies in cell and gene therapy drug delivery devices market, original equipment manufacturers, clinical trial scenario, and approved cell and gene therapy drug delivery devices. Scope of cell and gene therapy drug delivery devices, the clinical trial landscape of cell and gene therapies in China, the U.S, and across the world, challenges in cell and gene therapy drug delivery devices, and massive scope for adoption of cell and gene therapy drug delivery devices in emerging nations that can be leveraged by players operating in the market.

Data from different segments of the market has been analyzed minutely to gain a holistic view of the market. These segments include market by product type, commercialized drugs, and regions.

Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.

To emphasize the dominance of the intravenous catheter segment of cell and gene therapy drug delivery devices market by product segment over other segments under the product category of cell and gene therapy drug delivery devices market in 2020 and 2030, Raviteja Palakurthy, Senior Research Analyst BIS Research, states, "The reason for market growth and the dominance of intravenous catheter segment can be attributed to the increasing global usage of intravenous catheters to deliver drugs that are dosed frequently for fairly long periods of time and for specific disease conditions. For most of currently approved cell and gene therapies such as Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis, Zynteglo, and Tecartus intravenous catheter are used as its drug delivery device

Request for a Sample: bisresearch.com/requeste=download

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 20 leading companies, market participants, and vendors. The key players profiled in the report include Amgen, Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio, Inc., Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd (ViroMed Co., Ltd), Human Stem Cell Institute, Kite Pharma, Inc., Kolon Tissue Gene, inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., and Vericel Corporation.

The study also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.

Who should buy this report?

How can market intelligence on Cell and Gene Therapy Drug Delivery Devices add value to an organizations decision-making process?

Insightful Questions Covered to Enable Companies Take Strategic Decisions

About BIS Research:

BIS Researchis a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.

Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

BIS Research offers syndicate as well as, custom studies, and expert consultations to firms, providing them specific and actionable insights on novel technology markets, business models, and competitive landscape.

BIS Healthcare vertical offers intelligence in the healthcare technology market for Medical Devices, Digital Health, Life Sciences, Robotics and Imaging, Information Technology, Precision Medicine, and other emerging healthcare technologies, covering the entire industry spectrum. In the past 5 years, BIS Healthcare has published more than 50 reports under the precision medicine banner.

Additionally, BIS Research has been nominating Top 25 Voices in Precision Medicine on its Insight Monk platform for the past two years successfully.

This email address is being protected from spambots. You need JavaScript enabled to view it.

See the rest here:
BIS Research Study Highlights the Global Cell and Gene Therapy Drug Delivery Devices Market to Reach $10.82 Billion by 2030 investigated in the latest...

Related Post

Comments are closed.

Archives